Company profile
Aibotics Inc.
OTC: AIBT · Healthcare · Medical - Pharmaceuticals
#1155 of 1,422 Healthcare companies by revenue
EA Score
13DFH 9DQ 15GM —SS 33
v0.1 · 55/100 weight · provisional
↑ listing tenure, market scale · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$2.2M
Employees
1
as of 2026-08-27
Market cap
$176.2k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.2k$2.2k2025
Net income-$2.2M-$2.2M2025
Operating income-$1.8M-$1.8M2025
Total assets$874.7k$874.7k2025
Liabilities$4.8M$4.8M2025
Equity-$4.0M-$4.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aibotics Inc.’s revenue?
Aibotics Inc. booked $2.2k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -101500.3% net margin.
Peers · Healthcare
Aditxt, Inc.17DAccelera Innovations, Inc——Instadose Pharma Corp.——Atossa Therapeutics, Inc.30DQuantum Medical Transport, Inc.——Health Discovery Corporation——Neighbors
Miami-Dade →Key facts
CEOBenjamin Kaplan
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersMiami, FL
ExchangeOTC: AIBT
Employees1
IPO date2006-03-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.